Evidence map›Paper›PMID 27503873›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology.

Nihal Bakeer, Jeanne James, Swarnava Roy, Janaka Wansapura, Shiva Kumar Shanmukhappa, John N Lorenz, Hanna Osinska, Kurt Backer, Anne-Cecile Huby, Archana Shrestha and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 78 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. The Cardiopulmonary Complications of Sickle Cell Disease.Hematology/oncology clinics of North America · 2022
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Nihal BakeerDivision of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Jeanne JamesDivision of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Swarnava RoyDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Janaka WansapuraImaging Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Department of Physics, University of Colombo, Colombo 03, Sri Lanka;
Shiva Kumar ShanmukhappaDepartment of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
John N LorenzDepartment of Molecular and Cellular Physiology, University of Cincinnati, Cincinnati, OH 45267;
Hanna OsinskaHeart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Kurt BackerDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Anne-Cecile HubyDivision of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Archana ShresthaDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Omar NissDivision of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Robert FleckDepartment of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Charles T QuinnDivision of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Michael D TaylorDivision of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Enkhsaikhan PurevjavHeart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Bruce J AronowDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229.
Jeffrey A TowbinDivision of Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229;
Punam MalikDivision of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229; punam.malik@cchmc.org.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · USUniversity of Colombo · LK

Funding

Cincinnati Center of Excellence in Hemoglobinopathies ResearchU01HL117709 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI MALIK, PUNAM · 2013 to 2017
$8.9M
Hemostatic factors and sickle cell diseaseR01HL112603 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI FLICK, MATTHEW J., MALIK, PUNAM · 2012 to 2016
$1.9M
NHLBI NIH HHS R01 HL112603NHLBI NIH HHS U01 HL117709
6 · The paper itself

Abstract

Cardiopulmonary complications are the leading cause of mortality in sickle cell anemia (SCA). Elevated tricuspid regurgitant jet velocity, pulmonary hypertension, diastolic, and autonomic dysfunction have all been described, but a unifying pathophysiology and mechanism explaining the poor prognosis and propensity to sudden death has been elusive. Herein, SCA mice underwent a longitudinal comprehensive cardiac analysis, combining state-of-the-art cardiac imaging with electrocardiography, histopathology, and molecular analysis to determine the basis of cardiac dysfunction. We show that in SCA mice, anemia-induced hyperdynamic physiology was gradually superimposed with restrictive physiology, characterized by progressive left atrial enlargement and diastolic dysfunction with preserved systolic function. This phenomenon was absent in WT mice with experimentally induced chronic anemia of similar degree and duration. Restrictive physiology was associated with microscopic cardiomyocyte loss and secondary fibrosis detectable as increased extracellular volume by cardiac-MRI. Ultrastructural mitochondrial changes were consistent with severe chronic hypoxia/ischemia and sarcomere diastolic-length was shortened. Transcriptome analysis revealed up-regulation of genes involving angiogenesis, extracellular-matrix, circadian-rhythm, oxidative stress, and hypoxia, whereas ion-channel transport and cardiac conduction were down-regulated. Indeed, progressive corrected QT prolongation, arrhythmias, and ischemic changes were noted in SCA mice before sudden death. Sudden cardiac death is common in humans with restrictive cardiomyopathies and long QT syndromes. Our findings may thus provide a unifying cardiac pathophysiology that explains the reported cardiac abnormalities and sudden death seen in humans with SCA.

Indexed as

Anemia, Sickle CellAnimalsArrhythmias, CardiacCardiomyopathiesDeath, Sudden, CardiacDisease Models, AnimalElectrocardiographyGene Expression ProfilingHeart Failure, DiastolicHumansHypertension, PulmonaryMice, Inbred C57BLMice, KnockoutMice, TransgenicMyocardiumarrhythmiascardiomyopathyrestrictive physiologysickle cell anemiasudden death

Identifiers

PMID27503873
PMCPMC5024607
OpenAlexW2514180905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.